A pilot phase I clinical trial involving 15 infusions of anti-CD3 Â anti-CD20 bispecific Ab (CD20Bi)-armed anti-CD3-activated T cells (aATC) and low-dose IL-2 was conducted in three non-Hodgkin's lymphoma (NHL) patients (two high-risk and one refractory) after autologous SCT. The feasibility of T-cell expansion, safety of aATC infusions, cytotoxic immune responses and trafficking of aATC were evaluated. Three NHL patients received 15 infusions of 5 Â 10 9 aATC (three infusions/week for 3 weeks and one infusion/ week for 6 weeks) between days 1 and 65 after SCT with IL-2. There were no dose-limiting toxicities. Chills, fever, hypotension and malaise were the common side effects. Engraftment was delayed in one patient with a low stem cell dose. CD20Bi aATC infusions induced specific cytotoxicity directed at lymphoma targets. Endogenous peripheral blood mononuclear cells from two patients mediated anti-lymphoma cytotoxicity above preSCT background (Po0.001).
INTRODUCTION
Autologous SCT after high-dose chemotherapy (HDC) is considered the treatment of choice for patients with high-risk, refractory or relapsed non-Hodgkin's lymphomas (NHL) who have failed standard therapies. [1] [2] [3] [4] [5] [6] Not only are these high-risk and relapsed patients at greater risk of progressive disease after SCT, but also they are likely to have rituximab-resistant disease, which would limit the effectiveness of rituximab-containing preparative regimens.
CD20 is a 33-to 36-kD non-glycosylated phosphoprotein expressed on the cell membrane of mature B cells and not on B-cell precursors, stem cells, and plasma cells. Although its function is unknown, CD20 is expressed by more than 95% of B cells in NHL and other B-cell malignancies. Its distribution on malignant B cells and lack of modulation upon anti-CD20 bindings makes it an attractive therapeutic target. The anti-CD20 mAb used in this study is rituximab (Rituxan), which is a Food and Drug Administration-approved chimeric mAb that targets and kills CD20 þ lymphoma cells by antibody-dependent cell-mediated cytotoxicity, complement-mediated cytotoxicity and apoptosis. [7] [8] [9] [10] As a previous phase I clinical trial involving 15 infusions of unarmed anti-CD3-activated T cells (ATC), IL-2 and granulocyte macrophage colony-stimulating factor (GM-CSF) after HDC and SCT resulted in encouraging PFS of 50% and overall survival of 70% at 32 months of follow-up in women with stage IIIB/IV breast cancer, 11 we reasoned that multiple infusions of targeted ATC armed with anti-CD3 Â anti-CD20 bispecific antibody (CD20Bi) in combination with IL-2 would not only be feasible and safe, but also would enhance anti-lymphoma activity after HDC and SCT in high-risk or refractory NHL patients. In preclinical studies, we showed that when CD20Bi produced by chemically heterconjugating rituximab to anti-CD3 was used to arm ATC, there was marked enhancement of specific cytotoxicity directed at CD20 þ lymphoma cell lines. 12 Engagement of CD20Bi-armed ATC (aATC) with B9C lymphoma targets lead to lysis, Th 1 cytokine secretion and chemokine secretion in vitro. More importantly, ATC armed with CD20Bi killed a CD20 þ rituximab-resistant ARH-77 multiple myeloma cell line. 12 These data provided a strong rationale for infusing CD20-targeted ATC to treat resistant NHL after SCT. Our approach takes advantage of the non-major histocompatibility complex-restricted cytotoxicity mediated by anti-CD3-activated T cells [13] [14] [15] [16] by redirecting their cytotoxicity to CD20 þ tumor targets. Arming with CD20Bi makes every ATC into a CD20-specific cytotoxic lymphocyte.
This pilot study combined multiple infusions of CD20Bi aATC with IL-2 given between 1 and 69 days after SCT. Low-dose IL-2 was given to support in vivo T-cell proliferation. In this study, we attempted to ascertain whether: (1) it was feasible to grow T cells from the peripheral blood mononuclear cells (PBMCs) of heavily pretreated NHL patients; (2) it was safe and technically feasible to give 15 infusions of aATC with IL-2 early and later after SCT; (3) this combination would impair hematopoietic engraftment; (4) the infused aATC could be detected and their persistence was observed in the circulation; (5) there was a unique pattern of trafficking, localization and disappearance after infusion and (6) infusions of aATC could induce endogenous CTL. Our results show that CD20Bi aATC are safe and induce endogenous immune changes in function and phenotype.
MATERIALS AND METHODS

Trial design
We enrolled patients between 18 and 70 years of age with high-risk or refractory NHL with histologically confirmed CD20 þ NHL. (volume exhaled at the end of the first second of forced expiration) and DLCO (diffusion capacity for carbon monoxide) o45%; (2) creatinine 42.0 mg/dL or creatinine clearance of o60 mL/min; (3) liver function tests with direct bilirubin 42.0 mg/dL, serum glutamic-oxaloacetic transaminase (SGOT) or serum glutamic pyruvic transaminase (SGPT) 42.5 times normal or a history of severe hepatic dysfunction; (4) left ventricular ejection fraction o40% by muti-gated acquisition scan or echocardiogram at rest; (5) active infection or HIV antibody positivity and (6) Karnofsky performance status o60% or Eastern Cooperative Oncology Group performance status 42. Figure 1a shows the schema for the pilot study conducted at RWH, which involved three infusions per week of 5 Â 10 9 aATC for 3 weeks followed by one infusion per week for 6 subsequent weeks, starting on day þ 1 and ending on day 69 after SCT for a total dose of 75 Â 10 9 . The patients also received 300 000 IU/m 2 daily of s.c. IL-2 starting on day þ 4 and ending on the day of the last aATC infusion.
Production of heteroconjugated CD20Bi
Anti-CD20 (Rituximab; Genentech, SF, CA, USA) and anti-CD3 (muromonab-CD3, OKT3, Centrocor, Ortho-Biotech, Raritan, NJ, USA) were purchased from the hospital pharmacy and used to produce the CD20Bi. 17 Anti-CD3 and anti-CD20 were cross-linked with Traut's reagent (Pierce Biotechnology Inc., Rockford, IL, USA) and sulphosuccinimidyl 4-(Nmaleimidomethyl) cyclohexane-1-carboxylate (Pierce Biotechnology, Inc.), respectively. The crosslinked mAbs were heteroconjugated overnight. The extent of and heterconjugation was verified by SDS-polyacrylamide gel electrophoresis gels (4-15% gradient) that was stained with Gelcode Blue as previously described. 12, 17 Leukapheresis, T-cell expansion and arming of T cells with CD20Bi
PBMCs were collected by leukapheresis before mobilization for stem cells. PBMCs were activated with soluble anti-CD3 mAb and expanded in IL-2 (100 IU/mL) to generate ATC under cGMP conditions. 18, 19 Harvested cells were armed with 50 ng of CD20Bi/10 6 ATC, and cryopreserved in 15 aliquots. Aliquots of each bag were tested for bacterial and fungal contamination (RWMC Pathology Laboratory, Providence, RI, USA), endotoxin (Lonza, Inc., Walkersville, MD, USA), and mycoplasma (Bionique Testing Laboratories, Inc., Saranac Lake, NY, USA). Aliquots of the aATC product were retained for quality control testing for cytotoxicity directed at B9C targets and phenotyping by flow cytometry. 
Preparative regimen
Infusions of aATC
Patients routinely were pre-medicated with diphenhydramine (50 mg, orally or intravenously) and acetaminophen (1000 mg, orally) 30 min before initiation of aATC infusions to prevent chills and fever. Prehydration with 500 mL of normal saline was started 1 h before each infusion and IV hydration was continued at 200 mL/h until stable and then tapered. Cryopreserved aATC were thawed and infused at the bedside beginning 4 days after SCT. Infusions of aATC were given over 5-15 min and vital signs and O 2 saturations were monitored every 15 min up to 1 h postinfusions and then hourly until stable. If the systolic blood pressure dropped below 100 mm Hg, 500 mL boluses of fluid were given to maintain systolic blood pressure above 100 mm Hg.
Maximum tolerated dose, dose modifications and criteria for removal due to toxicity
In this pilot study, a dose of 5 Â 10 9 per infusion was used in combination with IL-2. All regimen-related and cell-based toxicities were separated and discussed by the attending team, scored and recorded. Patients who experienced grade 4 non-hematologic toxicity or persistent grade 3 cellbased toxicity (NCI Immunotherapy Toxicity Scoring) would be removed from the study. Infusions were held until cell-based toxicity improved to grade 0 or 1. All toxicities were assessed for 7 days after each infusion. Other reasons for removal from the protocol included initiation of other therapy, a patient's decision to stop, when it was deemed in the best interest of the patient, or an unexplained delay in treatment.
Trafficking of CD20Bi-armed ATC by indium labeling 
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Phenotyping and detection of aATC PBMC from the patients undergoing SCT were sequentially evaluated to assess changes in phenotyping. The cell product was stained for CD3
Cryopreserved leukapheresis PBMCs served as baseline controls. The flow cytometric assay for detecting murine IgG2a (OKT3)-positive cells (CD20Bi aATC) was optimized by spiking normal whole unfractionated blood with known proportions of aATC using FITC-conjugated goat antimouse IgG2a Ab.
Specific cytotoxicity directed at B9C cells
PBMCs were tested for specific cytotoxicity using 51 Cr release assay and labeled B9C cells. Fresh ficoll-hypaque-separated PBMC were plated into microwells containing labeled target cells in triplicate at 25:1 effector to target (E/T) ratio for 4 h at 37 1C. Specific lysis was calculated using the formula: [% specific lysis ¼ (test À spontaneous release)/(maximum release À spontaneous release) Â 100] expressed as mean ± s.d. from triplicate determinations. 12 Separation of IgG2a þ and IgG2a À populations Fresh PBMCs were separated into IgG2a-positive cells (aATC bearing murine IgG2a OKT3) and IgG2a-negative cells (endogenous lymphocyte populations) using Miltenyi beads (Miltenyi, Auburn, CA, USA) and tested for cytotoxicity directed at B9C at an E/T of 25:1. 20 
Statistical analyses
Nonparametric Mann-Whitney test was used to examine the average change in cytotoxicity against B9C cells using GraphPad Prism version 7.00 for Windows (GraphPad Software, San Diego, CA, USA). The Kaplan-Meier was performed using GraphPad Prism.
RESULTS
Patient characteristics
Two patients had failed first-line chemotherapy or did not achieve a CR after first-line chemotherapy but responded to RICE (FH01631 and FH01661). The third patient (FH01623) could not achieve a CR after salvage therapy and radiofrequency ablation of the lymphomatous mass in the left axilla. He was transplanted with refractory disease. The follow-up on these patients is reported as of 13 Feburary 2013. Table 1 Survival days after SCT.
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Mobilization of stem cells
Patients received G-CSF stimulation for 4 days for stem cell mobilization before leukapheresis to obtain a minimum CD34 þ cell dose of 2 Â 10 6 cells/kg. The median CD34 þ cell dose/kg was 4.03 Â 10 6 with a 95% confidence interval of 3.3, 6.9 Â 10 6 /kg. Table 1 shows the doses of CD34 þ cells infused into the patients. One patient (FH01623) required multiple attempts at stem cell mobilization and a bone marrow (BM) harvest to obtain 1.0 Â 10 6 CD34 þ cells/kg.
Engraftment of neutrophils, lymphocytes and monocytes
The mean day of neutrophil engraftment (neutrophil count X500/ mm 3 ) was 11.2 (s.d. ¼ 1.72) days with a median of 11.0 days. There were no delays in platelet recovery or need for extended transfusion support. Figure 2 shows the engraftment data in all three patients.
ATC characteristics
The planned aATC dose and the actual aATC dose are presented in Table 1 . The total number of T cells expanded after 14 days ranged from 98.8 to 140 Â 10 9 . In the expanded product, the median percent CD3, CD4 and CD8 cells were 95.3%, 55.4% and 48.9%, respectively (Supplementary Table 2 ). Expanded ATC armed with CD20Bi exhibited 2.8-20.3% specific cytotoxicity directed at CD20 þ B9C cells in 51 Cr release cytotoxicity assay at an E/T of 25:1. aATC derived from normal subjects (n ¼ 14) exhibited a mean of 30% ( ± 5.0). aATC infusions All three patients received a total of 7.5 Â 10 10 in 15 divided doses in the pilot study. Supplementary Table 3 (Supplementary Data) summarizes the side effects of the infusions. A typical pattern consisted of chills at B1 h, nausea at 1-2 h, headaches atB2-4 h, hypotension at B2-3 h and fever at 2-4 h after an infusion. The chills were controlled with Demerol and fever was controlled with alternating doses of ibuprofen 600 mg and acetaminophen 600 mg given orally every 6 h for 24 h. No one was removed from the study nor were there any delays in the infusion schedule because of cell-based toxicities.
Trafficking of indium-labeled CD20Bi-armed ATC CD20Bi-aATC localized to the BM, lung, liver and spleen within 1 h of injection. By 24 h, CD20Bi-aATC had cleared from the lungs but persisted and remained in the BM, liver and spleen at 48 and 72 h ( Figure 3 ).
Persistence of infused aATC
As OKT3 is a murine IgG2a mAb, the proportion of aATC could be enumerated in PBMC using FITC-conjugated goat anti-mouse IgG2a Ab. Two patients were tested for the kinetics of aATC survival in vivo. Patients FH01669 and FH01631 exhibited increases in the proportion of circulating aATC, which reached 25% at 8 h for FH01669 and 11% at 24 h for FH01631 after their second aATC infusion (Figure 4a ). IgG2a þ cells could be easily detected up to 48 h (Figure 4a ) and persisted at levels of 1-2% for 7 days (data not shown).
Tumor-specific response of endogenous immune cells In order to determine whether endogenous immune cells developed specific cytotoxic responses to B9C lymphoma targets, the infused (IgG2a þ CD20Bi aATC) were separated from the endogenous immune cells. IgG2a-positive cells (CD20Bi aATC) were enumerated using FITC-conjugated goat anti-mouse IgG2a Abs after the aATC infusions and separated by Miltenyi beads from the PBMC for cytotoxicity testing as described in methods. Our data show that specific anti-B9C cytotoxicity was positive in the endogenous population in two of three patients after 10 aATC infusions. Figure 4b shows a representative cytotoxicity data on the IgG2a-negative population, the unfractionated PBMC, the leukapheresis product, ATC and aATC for patient FH01661. The IgG2a-negative cells showed cytotoxicity against B9C comparable to unfractionated PBMC indicating a development of specific anti-B9C responses by endogenous cells. The cytotoxicity mediated by the IgG2a-negative cells was significantly higher (Po0.001) than the leukapheresis product, and ATC alone (Figure 4b ).
Post SCT infectious disease complications There were no fungal, bacterial or viral (HSV1 or 2, varicella zoster virus, respiratory syncitial virus) infections during the first 100 days after SCT.
DISCUSSION
The overarching long-term objective is to optimize anti-lymphoma activity when the tumor burden is at a minimum after HDC conditioning for SCT. This study builds on our prior study in women with metastatic breast cancer wherein unarmed ATC were infused on the same schedule in combination with IL-2. The idea of multiple infusions is to provide immune consolidation during immune reconstruction after myeloablation. The primary objective was to determine whether multiple infusions of targeted T cells could be given as frequently as three times a week for 3 weeks and then once a week for 6 weeks without causing dose limiting toxicities (DLTs). The secondary objectives were to determine how long aATC persist in the circulation, the aATC trafficking pattern, and whether multiple infusions could induce development of endogenous cytotoxicity directed at CD20 þ lymphoma targets.
The strategy of rituximab preSCT treatment or consolidation to reduce relapse after SCT has been encouraging. [21] [22] [23] [24] [25] Therefore, this pilot provides strong rationale for giving frequent infusions during the first 3 months after SCT to maintain a pool of targeted T cells early after HDC during the period of minimal residual disease to purge residual disease and to consolidate the anti-lymphoma activity during the 'immunologic space' created by HDC.
The lack of immunologic storm may be due to the paucity of endogenous lymphocytes and their functional immunodeficiency in the first 3 months after SCT. In contrast to the infusions of chimeric Ab receptors (scFV anti-CD19 antibody), transduced anti-CD3/anti-CD28 coactivated T cells following myeloablation and SCT, 26, 27 the addition of multiple infusions of 5 Â 10 9 CD20Bi-armed ATC in combination with IL-2 did not markedly enhance cell-based toxicities. There were no short-or long-term side-effects such as cytokine storm or persistent non-hematologic grade 3 toxicities related to cell infusions. Infusions did not impair the performance status of the patients. The infusions were associated with no side effects or mild flu-like symptoms that were easily controlled with demerol, anti-pyretics or vigorous hydration. After discharge from the BMT units, infusions were given in the BMT outpatient clinic. There were no DLTs and no patient required pressors, intubation or hospital admission. The lack of brisk cytokine responses induced by infusions of CD20Bi aATC infusions may be due to the functional nature of infused aATC and the relative lack and relative non-responsiveness of the endogenous immune cells for the aATC during the first weeks to months after SCT. The side-effects were even less those that observed in women with metastatic breast cancer who received eight infusions of anti-CD3 Â anti-Her2 bispecific Ab aATC in combination with low-dose IL-2 and GM-CSF without immediately preceding chemotherapy (46 weeks). These women experience grade 3 chills and hypotension, grade 1-2 fevers, headaches and fatique. 28 The cytokine responses to armed ATC infusions were more like 'flurries' as opposed to the 'storm' seen with direct infusions of bispecific antibodies 29, 30 or infusions of anti-CD3/anti-CD28 costimulated T cells transduced with scFv anti-CD19 chimeric Ab receptor. 26, 27 In a separate study using 4 weekly infusions of CD20Bi-armed ATC given without IL-2 supplementation starting 4 days after SCT, infusions induced a Th1 pattern and levels of IL-2R, IL-12, CXCL10 and CXCL9 increased during the first 3 months after SCT. 31 It is likely that 15 infusions induced comparable or more persistence levels of these cytokines and chemokines.
Neutrophils engrafted by day 11 after SCT in two patients who had adequate numbers of CD34 þ cells in the stem cell product without therapeutic doses of G-CSF or GM-CSF suggesting that the infusions of aATC may have provided cytokines/chemokines that facilitated engraftment and were not detrimental to the engraftment process. Lymphocyte engraftment (4500/mm 3 ) was observed as early as days 8 and 9 after SCT in the two patients who had adequate numbers of CD34 þ cells in their stem cell inoculum. There was a transient increases in the absolute lymphocyte counts between the days 20 and 30 post SCT in two of three patients (upper and lower panel, Figure 2 ), suggesting there was some in vivo proliferation of the infused T cells. Although patient #3 had delayed neutrophil and platelet engraftment, the patient had expansion of the lymphocytes that peaked at 2400/mm 3 day 27 after SCT. The late engraftment of neutrophils and platelets was likely due to the very low numbers of CD34 þ cells in a stem cell product that was infused (G-CSFmobilized CD34 þ cells obtained by leukapheresis and G-CSFstimulated BM) and not due to the detrimental effect of aATC. Our preclinical studies in a murine model showed that anti-CD3-activated murine T cells can enhance engraftment of lethally irradiated mice given an engraftment-limiting dose of splenocytes containing hematopoietic precursors. 32, 33 Despite a total CD34 þ cell dose of 1.0 Â 10 6 /kg, patient #3 engrafted without infections or other complications in the absence of G-CSF supplementation.
Phenotyping after SCT showed a PBMC population skewed toward CD4 þ cells most likely reflecting the product, which contained B50% CD4 þ cells and the CD4 þ population would be the population that would proliferate. The levels of aATC peaked as high as 25% at 8 h for FH01669 and 11% at 24 h for FH01631 after two infusions. aATC could be detected at 1-2% for 7 days. Infusion of 111 In-labeled aATC revealed trafficking to the lungs at 1 h and to the liver, spleen and BM by 24 h.
Cytotoxicity was detected in the infused aATC as well as the endogenous immune cells. In two patients, the purified aATC (IgG2a þ cells) and endogenous immune cytotoxicity-mediated IgG2a þ -depleted fresh PBMCs were clearly higher after SCT than the preSCT baseline. The cytotoxicity mediated by IgG2a þ cells show that the aATC-enriched population retained its cytotoxic ability and retained enough CD20Bi on their surface to be detected by flow cytometry. It is not clear whether effector-and/or central memory phenotypes are responsible for mediating the cytotoxicity in the IgG2a-depleted population. Additional studies are warranted to identify the T-cell subsets responsible for mediating the cytotoxicity.
In summary, we showed that 15 infusions of ATC armed with CD20Bi given in the first 69 days after SCT were safe. Although this trial did not evaluate clinical efficacy, we showed that expansion from heavily pretreated NHL patients was feasible, was safe without dose-limiting toxicity, the infused cells persisted and trafficked to the lungs and then to the liver, spleen and BM. Both the infused and endogenous immune cells exhibited antilymphoma activity. Two of three patients are alive and disease free 2790 and 2660 days after SCT without rituximab consolidation or maintenance therapy. These results provide encouraging data for the design of targeted therapy in combination with SCT for patients with CD20 þ disease who are refractory to treatment.
Lessons learned from this pilot study can be immediately translated in the design of future adoptive targeted T-cell approaches. Future trials can be designed to take advantage of the induction of anti-lymphoma responses or the boosting of such responses early after SCT particularly in refractory lymphoma patients by multiple infusions of autologous or potentially allogeneic-irradiated targeted T cells. In a recent study, we showed that irradiated ATC armed with BiAb continue to exhibit cytotoxicity, 34 therefore, more potent healthy allogeneic ATC can be armed with CD20Bi to target lymphoma post autologous SCT.
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